文献速递自身炎症与 IgG4 相关病

AA型淀粉样变 complicating 冷吡啉相关周期性综合征:86例研究包含23例法国患者及系统综述

AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究回顾性分析法国23例及文献63例共86例CAPS合并AA淀粉样变患者,诊断中位年龄39岁,MWS最常见(62例),R260W突变为最常见(60%)。28例(33%)接受IL-1抑制剂,89%病例蛋白尿下降>50%;35例(41%)死亡,均未接受IL-1抑制剂。

要点

  • AA淀粉样变可发生于几乎所有CAPS亚型,包括MWS、FCAS及重叠型。
  • IL-1抑制剂治疗可使89%患者蛋白尿下降>50%。
  • 死亡患者均未接受IL-1抑制剂,提示早期诊断并尽早治疗的必要性。

核心结论

  • AA淀粉样变可发生于几乎所有CAPS亚型。
  • IL-1抑制剂有效,强调了对AA-CAPS患者尽早诊断并尽早开始该治疗的必要性。

研究设计与样本

  • 法国回顾性研究联合系统文献综述,共纳入86例患者(23例法国新病例,63例来自文献)。

主要发现

  • AA淀粉样变诊断中位年龄为39岁。
  • CAPS亚型分布:MWS 62例,FCAS 9例,MWS与FCAS交界型12例,CINCA与MWS交界型3例。
  • 60例(70%)患者进行了NLRP3测序,最常见突变为R260W(60%)。
  • 3例AA-CAPS患者携带体细胞NLRP3突变。
  • 35例(41%)死亡,均未接受过IL-1抑制剂。

关键数值与推荐

  • 蛋白尿下降>50%:IL-1抑制剂治疗患者中89%达到。
  • NLRP3测序率70%(60/86),R260W突变占60%。

临床怎么用

  • 原文结论指出IL-1抑制剂有效,并强调对AA-CAPS患者尽早诊断以尽早开始该治疗的必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cryopyrin-associated periodic syndrome (CAPS) is a rare but treatable inherited autoinflammatory condition including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurologic cutaneous articular syndrome (CINCA). Our objective was to describe the main features of CAPS AA amyloidosis (AA-CAPS) associated and the efficacy of IL-1 inhibitors in this indication. METHODS: Retrospective study in France associated with a systematic literature review. RESULTS: Eighty-six patients were identified: 23 new French cases and 63 from the literature, with a median age at amyloidosis diagnosis of 39 years old. CAPS subtypes were MWS (n = 62), FCAS (n = 9), frontier forms between MWS and FCAS (n = 12) and between CINCA and MWS (n = 3). NLRP3 had been sequenced in 60 patients (70%) and the most frequent mutation was R260W (60%). Three AA-CAPS patients displayed somatic NLRP3 mutations. Death occurred in 35 patients (41%), none of whom having ever received IL-1 inhibitors. Twenty-eight patients (33%) received IL-1 inhibitors, with a >50% decrease in proteinuria in 89% of cases. CONCLUSION: AA amyloidosis can occur in nearly all CAPS subtypes. IL-1 inhibitors are effective, underlining the necessity of an early diagnosis of CAPS in order to start this treatment as soon as possible among AA-CAPS patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rodrigues F, Cuisset L, Cador-Rousseau B, et al. AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Rheumatology (Oxford). 2022. PMID: 35262642. doi:10.1093/rheumatology/keac145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。